A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Atopaxar (Primary)
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Adverse reactions
  • Acronyms LANCELOT-CAD
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 27 Mar 2012 Biomarker results presented at the 61st Annual Scientific Session of the American College of Cardiology.
    • 09 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top